Skip to main content
Top
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B

Authors: Sarah Maylin, Jean-Marie Sire, Papa Saliou Mbaye, François Simon, Anna Sarr, Marie-Louise Evra, Fatou Fall, Jean Daveiga, Aboubakry Diallo, Jean-Marc Debonne, Loic Chartier, Muriel Vray

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

We evaluated the short-term spontaneous fluctuations of HBV DNA and HBsAg levels in Senegalese patients with chronic infection with hepatitis B virus and normal ALT and determined factors related to these fluctuations.

Method

A total of 87 patients with persistent normal ALT values were enrolled in the study. Serum samples were obtained at three different visits, with an interval of 2 months (M0, M2, and M4), and without initiating anti HBV treatment. Levels of HBV DNA, quantitative HBsAg, ALT and AST, genotyping and viral DNA mutations were analyzed.

Results

Among the 87 patients, genotype E was predominant (75%). The median HBV DNA level was 2.9 log10 IU/mL [2.2-3.4], 2.7 log10 IU/mL [2.1-3.6] and 2.7 log10 IU/mL [2.1-3.4] at M0, M2 and M4, respectively. The values ranged from <1.1 to 7 log10 IU/mL and 55 (63%) had HBV DNA fluctuations ≥ 0.5 log10 IU/mL between two visits. Patients in whom HBV DNA fluctuated ≥0.5 log10 IU/mL between M0 and M2 also had significant fluctuations between M2 and M4, while patients with stable HBV DNA between M0 and M2 showed a stable viral load between M2 and M4. The only factor found to be associated with HBV DNA fluctuations ≥ 0.5 log10 IU/mL was a low BMI (<21 kg/ m2). HBsAg levels were not correlated with HBV DNA levels.

Conclusion

Sixty-three percent of the enrolled Senegalese population showed a large, short-term fluctuation of HBV DNA levels. Such fluctuations may have an impact on therapeutic management, requiring closer monitoring.
Literature
1.
go back to reference Lavanchy D. Hepatitis B, virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.CrossRefPubMed Lavanchy D. Hepatitis B, virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.CrossRefPubMed
3.
go back to reference Etard J-FColbachini P, Dromigny JA, Perrier-Gros-Claude JD. Hepatitis C antibodies among blood donors, Senegal, 2001. Emerg Infect Dis. 2003;9(11):1492–3.CrossRef Etard J-FColbachini P, Dromigny JA, Perrier-Gros-Claude JD. Hepatitis C antibodies among blood donors, Senegal, 2001. Emerg Infect Dis. 2003;9(11):1492–3.CrossRef
4.
go back to reference Vray M, Debonne JM, Sire JM, Tran N, Chevalier B, Plantier JC, et al. Molecular epidemiology of hepatitis B virus in Dakar, Sénégal. J Med Virol. 2006;78(3):329–34.CrossRefPubMed Vray M, Debonne JM, Sire JM, Tran N, Chevalier B, Plantier JC, et al. Molecular epidemiology of hepatitis B virus in Dakar, Sénégal. J Med Virol. 2006;78(3):329–34.CrossRefPubMed
5.
go back to reference European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol Juill. 2012;57(1):167–85.CrossRef European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol Juill. 2012;57(1):167–85.CrossRef
6.
go back to reference Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8(5):275–84.PubMed Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8(5):275–84.PubMed
7.
go back to reference Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat. 2008;15(6):434–41.CrossRefPubMed Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat. 2008;15(6):434–41.CrossRefPubMed
8.
go back to reference Chun YK, Kim JY, Woo HJ, Oh SM, Kang I, Ha J, et al. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection. Hepatology. 2000;32(5):1154–62.CrossRefPubMed Chun YK, Kim JY, Woo HJ, Oh SM, Kang I, Ha J, et al. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection. Hepatology. 2000;32(5):1154–62.CrossRefPubMed
9.
go back to reference Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51(6):1933–44.CrossRefPubMed Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51(6):1933–44.CrossRefPubMed
10.
go back to reference Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 2010;52(4):1232–41.CrossRefPubMed Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 2010;52(4):1232–41.CrossRefPubMed
11.
go back to reference Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int Févr. 2013;33 Suppl 1:125–32.CrossRef Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int Févr. 2013;33 Suppl 1:125–32.CrossRef
12.
go back to reference Gauthier M, Bonnaud B, Arsac M, Lavocat F, Maisetti J, Kay A, et al. Microarray for hepatitis B virus genotyping and detection of 994 mutations along the genome. J Clin Microbiol. 2010;48(11):4207–15.CrossRefPubMedPubMedCentral Gauthier M, Bonnaud B, Arsac M, Lavocat F, Maisetti J, Kay A, et al. Microarray for hepatitis B virus genotyping and detection of 994 mutations along the genome. J Clin Microbiol. 2010;48(11):4207–15.CrossRefPubMedPubMedCentral
13.
go back to reference Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods. 2004;115(2):217–22.CrossRefPubMed Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods. 2004;115(2):217–22.CrossRefPubMed
14.
go back to reference Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49(4):1151–7.CrossRefPubMed Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49(4):1151–7.CrossRefPubMed
16.
go back to reference Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57(2):441–50.CrossRefPubMed Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57(2):441–50.CrossRefPubMed
17.
go back to reference Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis. 2013;17(3):399–412.CrossRefPubMed Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis. 2013;17(3):399–412.CrossRefPubMed
18.
go back to reference Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5(12):1462–8.CrossRefPubMed Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5(12):1462–8.CrossRefPubMed
19.
go back to reference Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52:508–13.CrossRefPubMed Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52:508–13.CrossRefPubMed
20.
go back to reference Jaroszewicz J, Calle Serrano B, Serrano B, Wursthorn K, Deterding K, Schlue J, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52:514–22.CrossRefPubMed Jaroszewicz J, Calle Serrano B, Serrano B, Wursthorn K, Deterding K, Schlue J, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52:514–22.CrossRefPubMed
21.
go back to reference Song JC, Min BY, Kim JW, Kim JY, Kim YM, Shin CM, et al. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol. 2011;17(4):268–73. doi:10.3350/kjhep.2011.17.4.268.CrossRefPubMedPubMedCentral Song JC, Min BY, Kim JW, Kim JY, Kim YM, Shin CM, et al. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol. 2011;17(4):268–73. doi:10.3350/kjhep.2011.17.4.268.CrossRefPubMedPubMedCentral
22.
go back to reference Tuaillon E, Mondain AM, Nagot N, Ottomani L, Kania D, Nogue E, et al. Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes. PLoS One. 2012;7(3):e32143.CrossRefPubMedPubMedCentral Tuaillon E, Mondain AM, Nagot N, Ottomani L, Kania D, Nogue E, et al. Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes. PLoS One. 2012;7(3):e32143.CrossRefPubMedPubMedCentral
23.
go back to reference Neumann AU, Phillips S, Levine I, Ijaz S, Dahari H, Eren R, et al. Novel mechanism of antibodies to hepatitis b virus in blocking viral particle release from cells. Hepatology. 2010;52(3):875–85.CrossRefPubMedPubMedCentral Neumann AU, Phillips S, Levine I, Ijaz S, Dahari H, Eren R, et al. Novel mechanism of antibodies to hepatitis b virus in blocking viral particle release from cells. Hepatology. 2010;52(3):875–85.CrossRefPubMedPubMedCentral
24.
go back to reference Neumann AU. Hepatitis B, viral kinetics: a dynamic puzzle still to be resolved. Hepatology. 2005;42(2):249–54.CrossRefPubMed Neumann AU. Hepatitis B, viral kinetics: a dynamic puzzle still to be resolved. Hepatology. 2005;42(2):249–54.CrossRefPubMed
Metadata
Title
Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B
Authors
Sarah Maylin
Jean-Marie Sire
Papa Saliou Mbaye
François Simon
Anna Sarr
Marie-Louise Evra
Fatou Fall
Jean Daveiga
Aboubakry Diallo
Jean-Marc Debonne
Loic Chartier
Muriel Vray
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-0881-4

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.